50 patients from each participating hospital that will receive Omega-3 supplementation (300-400mg EPA & 200-300mg DHA) per day for 8 consecutive months up to 10 months.
in addition to experimental treatment this group will receive the traditional treatment of deferoxamine/deferasirox plus regular blood transfusion with dose de-escalation methods till efficacy of experimental treatment proved.

50 patients from each participating hospital that will receive Nigella sativa supplementation (1g black seed oil contain 1% thymoquinone) per day for 8 consecutive months up to 10 months.
in addition to experimental treatment this group will receive the traditional treatment of deferoxamine/deferasirox plus regular blood transfusion with dose de-escalation methods till efficacy of experimental treatment proved.

50 patients from each participating hospital that will receive hydroxyurea medication (5 to 15mg/kg) per day for 8 consecutive months up to 10 months.
in addition to the experimental treatment, this group will receive the traditional treatment of deferoxamine/deferasirox plus regular blood transfusion with dose de-escalation methods until the efficacy of experimental treatment proved.

50 patients from each participating hospital that will receive natural honey(2.5 mg/kg dissolved in 250 ml water) per day for 8 consecutive months up to 10 months.
in addition to the experimental treatment, this group will receive the traditional treatment of deferoxamine/deferasirox plus regular blood transfusion with dose de-escalation methods until the efficacy of experimental treatment proved.

50 patients from each participating hospital that will receive the ordinary treatment of iron chelator agent of deferoxamine or deferasirox (SubQ infusion: 20 to 40 mg/kg/day over 8 to 12 hours, 6 to 7 nights per week, maximum daily dose: 40 mg/kg/day)for 8 consecutive months up to 10 months.
in addition to iron chelator agent, this group receive regular blood transfusion session.

Iron Overload

Oxidative Stress

Thalassemia Major

Omega-3 supplementation (300-400mg EPA & 200-300mg DHA) per day for 8 consecutive months up to 10 months

Omega 3

Nigella sativa supplementation (1g black seed oil contain 1% thymoquinone) per day for 8 consecutive months up to 10 months

Nigella Sativa Oil

hydroxyurea medication (5 to 15mg/kg) per day for 8 consecutive months up to 10 months.

Hydroxyurea

Natural honey(2.5 mg/kg dissolved in 250 ml water) per day for 8 consecutive months up to 10 months.

Honey

deferoxamine (SubQ infusion: 20 to 40 mg/kg/day over 8 to 12 hours, 6 to 7 nights per week, maximum daily dose: 40 mg/kg/day)for 8 consecutive months up to 10 months.

Deferoxamine

Regular blood transfusion session based on patient hematological profile starts from one session every 2 weeks.

blood transfusion session

Faculty of medicine, Beni-suef univeristy - Beni-Suef university hospital

Faculty of Pharmacy, Beni-Suef university

Health insurance hospital

Maternity and Children hospital

Hydroxy Urea, Omega 3, Nigella Sativa,Honey on Oxidative Stress and Iron Chelation in Pediatric Major Thalassemia

Impact of Combination Therapy Between Hydroxy Urea, Omega 3, Nigella Sativa and Honey on Antioxidant-oxidant Status and Reduction of Iron Overload in Pediatric Major Thalassemia

plasma F 2 -isoprostanes Picograms Per Millilitre measured by high pressure liquid chromatography assay

Total cholesterol milligrams per deciliter

Serum total iron micrograms per decilitre

C-reactive protein milligrams per deciliter

Total Iron Binding Capacity micrograms per decilitre

mean corpuscular hemoglobin (MCH) Picograms Per Millilitre

Chelation activity of Ferric - thymoquinone complex in percentage measured by high pressure liquid chromatography coupled with gaschromatography - mass spectroscopy analysis

Chelation activity of Ferrous - thymoquinone complex in percentage measured by high pressure liquid chromatography coupled with gaschromatography- mass spectroscopy analysis

Lactic acid dehydrogenase unit per litter

hemoglobin- F level in gram per deciliter

Reticulocyte absolute count in a cubic milliliter of blood

White blood cells count in a cubic milliliter of blood

Mohamed Medhat Abdelwahab Gamaleldin

Dr.Mohamed Medhat Abdelwahab Gamaleldin

Beni-Suef University

Maternity and Children Hospital, Makkah

Department of clinical pharmacy, faculty of pharmacy, Beni-suef univeristy

Beni-Suef Health insurance hospital

University of Arizona

College of Pharmacy,Department of Pharmacy Practice,University of Arizona

Four experimental groups, one control group.
Each experimental group receives different experimental treatments plus traditional treatment in the hospital and the control group receives only traditional treatment.

Evaluation of Nutritional Status in Thalassemia Major Patients in Assiut Children Hospital

Evaluation of Nutritional Status in Patients With Thalassemia Major in Assiut University Children Hospital

prevalence of malnutrition among thalassemic children attending assiut university children hospital

determination of the most common causes responsible for poor growth seen in thalassemic patients

decrease morbidity by providing possible strategies for early prevention of the problem of poor growth occurring in patients with thalassemia major

ARAbdelmonem

resident doctor of pediatrics

Assiut University

A single dose (20 mg/kg/day) of study drug will be taken once per day by mouth.

Beta Thalassemia Intermedia

Oral capsules, dose 20 mg/kg/day, once per day for 26 weeks

Sodium 2,2 dimethylbutyrate

Chronic Care Center

Trial of HQK-1001 in Beta Thalassemia Intermedia in Lebanon

An Open-Label Phase 2 Study of HQK-1001 in Subjects With Beta Thalassemia Intermedia

Baseline hemoglobin levels will be determined in each subject and averaged from levels obtained on a screening visit and on day one of the study, before any drug is taken. Hemoglobin levels will then be analyzed every 4 weeks during 26 weeks of taking the study drug and for 4 weeks after the dosing is completed. Changes from baseline will be determined.

Adverse events which occur during HQK-1001 administration for 26 weeks will be recorded every 4 weeks.

Levels of HbF will be averaged from a screening visit and day 1 of the study, prior to any drug treatment. HbF levels will then be measured every 4 weeks during treatment and for 4 weeks after the treatment, and compared to each subject's baseline value. The number of subjects in which an increase in HbF develops above individuals' average baseline value will be obtained.

Boston University

HemaQuest Pharmaceuticals Inc.

All patients will receive monthly phlebotomies.

beta-thalassemia/fatigue

Hydroxy Urea, Omega 3, Nigella Sativa,Honey on Oxidative Stress and Iron Chelation in Pediatric Major Thalassemia

Evaluation of Nutritional Status in Thalassemia Major Patients in Assiut Children Hospital

Trial of HQK-1001 in Beta Thalassemia Intermedia in Lebanon

Safety and Efficacy of Iron Reduction by Phlebotomy

Išsamiausia vaistinių žolelių duomenų bazė, paremta mokslu